Sector News

Juno Therapeutics soars on report of Celgene deal talks

January 18, 2018
Life sciences

Juno Therapeutics shares soared more than 50 percent in premarket trading after The Wall Street Journal reported the biotech company is in talks to be acquired by Celgene.

Shares of Juno rose $26.71 to $72.31 in premarket trading on Wednesday morning. The Seattle-based company had a market share of about $5.2 billion as of Tuesday.

Celgene is seeking to broaden its portfolio of blood-cancer drugs before Revlimid, its top-selling drug, loses its patent protection, The Journal noted. Juno’s approach is focused on developing treatments that use the body’s immune system to fight cancer.

The acquisition discussions could result in a deal within weeks, although it’s unclear how much Celgene would pay for Juno, The Journal added.

Source: CBS News

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach